SEC Form 4Coverage since Jun 4, 2026
$ADPT insider trading
Over the last 12 months, Adaptive Biotechnologies insiders reported no purchases and 14 sales totaling $31.5M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $31.5M 14 events
- Events · 12m
- 14 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $ADPT · 12Mvia TradingView
Top insiders · 12m
BOBULSKY SUSANChief Commercial Officer, MRD6× · $552K
LO FRANCISChief People Officer3× · $5.2M
ROBINS HARLAN SChief Scientific Officer3× · $21.1M
GRIFFIN MICHELLE RENEE—1× · $1.1M
BENZENO SHARONChief Commercial Ofc Imm Med1× · $3.5M
All insider trades
14 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 1,299 | $24 | $31K | -0.3% | plan |
| Jul 21, 2026 | ROBINS HARLAN SChief Scientific Officer · O | ▼ Sale | 492,400 | $21.89 | $10.8M | -37.7% | plan · 2 tranches |
| Jul 16, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 5,000 | $23 | $115K | -1.2% | plan |
| Jul 15, 2026 | LO FRANCISChief People Officer · O | ▼ Sale | 105,762 | $22.59 | $2.4M | -31.4% | plan |
| Jul 2, 2026 | ROBINS HARLAN SChief Scientific Officer · O | ▼ Sale | 386,240 | $22.01 | $8.5M | -27.5% | plan · 2 tranches |
| Jul 2, 2026 | LO FRANCISChief People Officer · O | ▼ Sale | 95,842 | $22.51 | $2.2M | -29.3% | plan · 3 tranches |
| Jul 1, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 487 | $22 | $11K | -0.1% | plan |
| Jun 29, 2026 | BENZENO SHARONChief Commercial Ofc Imm Med · O | ▼ Sale | 165,802 | $21.13 | $3.5M | -42.8% | plan · 2 tranches |
| Jun 25, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 5,000 | $20.5 | $103K | -1.2% | plan |
| Jun 25, 2026 | GRIFFIN MICHELLE RENEED | ▼ Sale | 52,084 | $20.18 | $1.1M | -76.9% | plan |
| Jun 16, 2026 | ROBINS HARLAN SChief Scientific Officer · O | ▼ Sale | 106,160 | $17.41 | $1.8M | -7% | plan · 2 tranches |
| Jun 11, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 5,000 | $19 | $95K | -1.2% | plan |
| Jun 4, 2026 | LO FRANCISChief People Officer · O | ▼ Sale | 39,741 | $17.49 | $695K | -13.7% | plan |
| Jun 4, 2026 | BOBULSKY SUSANChief Commercial Officer, MRD · O | ▼ Sale | 11,000 | $18 | $198K | -2.6% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ADPT feed.